Back to today’s briefing

Story perspectives

Novo Nordisk's Weight Loss Drug Outshines Eli Lilly's Trial Data

8/24/2025

43 9

Summary

Story summary

Eli Lilly and Novo Nordisk are pending full phase three trial data for their weight loss drugs.
Novo Nordisk's oral semaglutide demonstrates a higher weight loss of up to 16.6%, compared to Eli Lilly's 12.4%.
Both drugs mainly cause gastrointestinal side effects; Eli Lilly's has a 10.3% discontinuation rate due to these effects.
Pricing strategies are unclear, with potential competition affecting market dynamics.

1 of 1

Story summary

Eli Lilly and Novo Nordisk are pending full phase three trial data for their weight loss drugs.
Novo Nordisk's oral semaglutide demonstrates a higher weight loss of up to 16.6%, compared to Eli Lilly's 12.4%.
Both drugs mainly cause gastrointestinal side effects; Eli Lilly's has a 10.3% discontinuation rate due to these effects.
Pricing strategies are unclear, with potential competition affecting market dynamics.